RAMAT GAN, Israel--(BUSINESS WIRE)--Zetiq Technologies, a subsidiary of Bio-Light Ltd., has successfully completed the first arm of its cervical cancer clinical trial, aimed at identifying and diagnosing cervical cancer in biopsies via the Zetiq proprietary differential coloring stain. The goal of the trial was to demonstrate and measure the ability of Zetiq's technology to accurately diagnose the presence of cervical cancer cells and the stage of the disease, including in early stages of malignancy, in cervical biopsies.